Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-12-04
2007-12-04
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S255050, C514S256000, C514S275000, C544S122000, C544S316000, C544S331000, C544S333000
Reexamination Certificate
active
10424280
ABSTRACT:
Described herein are compounds that are useful as protein kinase inhibitors having the formula:wherein A1, A2, TmR1, X, R2, R3, R9, R12, and R13are as described in the specification. The compounds are especially useful as inhibitors of ERK2, Aurora2, GSK3, CDK2, AKT3, and ROCK protein kinases and for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, neurodegenerative disorders, inflammatory disorders, restenosis, diabetes, and cardiovascular disease.
REFERENCES:
patent: 6743791 (2004-06-01), Cao et al.
patent: WO 01/56993 (2001-08-01), None
patent: WO 01/57022 (2001-08-01), None
patent: WO 02/064586 (2002-08-01), None
patent: WO 02/079193 (2002-10-01), None
Tanaka et al., PubMed Abstract (Cell 108(3):317-29) Feb. 2002.
Rogers et al., PubMed Abstract (J Cell Biol. 157(2):219-29) Epub Apr. 2002.
Casanova et al., PubMed Abstract (Rev Neurol. 28(9):909-15), May 1999.
Hardt et al., Glycogen Synthase Kinase-3beta—A novel regulator of cardiac hypertrophy and development, Circulation Research, 90:1055-63, 2002.
Douglas, Jr., Introduction to Viral Diseases, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 1739-1747, 1996.
Damasio, Alzheimer's Disease and related dementias, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 1992-1996, 1996.
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20thEdition, vol. 1, pp. 1004-1010, 1996.
Layzer, Degenerative Diseases of the Nervous System, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 2050-2057, 1996.
Haar et al., CAPLUS Abstract 137:370099 (2002).
Chang et al. “Role of cAMP-dependent pathway in eosinophil apoptosis and survival,” Cell. Immunology. 203(1):29-38 (2000).
Frey et al. “TGF-beta regulation of mitogen-activated protein kinases in human breast cancer cells,” Cancer Letters 117(1):41-50 (1997).
Fukunaga et al. “Role of MAP kinase in neurons,” Molecular Neurobiology 16(1):79-95, (1998).
Hoshino et al., “Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors,” Oncogene 18:813-22 (1999).
Hu et al. “Protein kinase and protein phosphatase expression in amyotrophic lateral sclerosis spinal cord,” J. Neurochemistry. 85(2):432-42 (2003).
Illenberger et al. “The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: Implications for Alzheimer's disease,” Molecular Biology of The Cell 9(6):1495-512 (1998).
Kodama et al. “Significance of ERK cascade compared with JAK/STAT and PI3-K pathway in gp130-mediated cardiac hypertrophy,” Am. J. Physiol. Heart Circ. Physiol. 279(4):H1635-44 (2000).
Kortylewski et al “Mitogen-activated protein kinases control p27/Kip1 expression and growth of human melanoma cells,” Biochemical Journal 357(Pt 1):297-303 (2001).
Lee et al. “ICAM-1-induced expression of proinflammatory cytokines in astrocytes: Involvement of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways,” The Journal of Immunology 165(8):4658-66 (2000).
Moses et al. “Injury-induced osteopontin gene expression in rat arterial smooth muscle cells is dependent on mitogen-activated protein kinases ERK1/ERK2,”Arch. Biochem. Biophys. 396(1):133-7 (2001).
Namura et al. “Intravenous administration of MEK inhibitor U0126 affords brain protection against forebrain ischemia and focal cerebral ischemia,” Proc. Natl. Acad. Sci. U S A 98(20):11569-74 (2001).
Pintucci et al. “Lack of ERK activation and cell migration in FGF-2-deficient endothelial cells,”FASEB J. 16(6):598-600 (2002).
Putz et al. “Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines,” Cancer Research 59(1):227-33 (1999).
Raghunandan et al. “Hyperphosphorylation of the cytoskeletal protein Tau by the MAP-kinase PK40erk2: Regulation by prior phosphorylation with cAMP-dependent protein kinase A,” Biochemical and Biophysical Research Communications 215(3):1056-66 (1995).
Slevin et al. “Activation of MAP kinase (ERK-1/ERK-2), tyrosine kinase and VEGF in the human brain following acute ischaemic stroke,” NeuroReport 11(12):2759-64 (2000).
Tack et al. “Autocrine activation of the IGF-1 signaling pathway in mesangial cells isolated from diabetic NOD mice,” Diabetes 51(1):182-8 (2002).
Takeishi et al. “Activation of mitogen-activated protein kinases and p90 ribosomal S6 kinase in failing human hearts with dilated cardiomyopathy,”Cardiovasc. Res. 53(1):131-7 (2002).
Aronov Alexander
Hale Michael Robin
Maltais Francois
Straub Judith
Tang Qing
Pearson Daniel A.
Rao Deepak
Vertex Pharmaceuticals Incorporated
LandOfFree
Heterocyclic inhibitors of ERK2 and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic inhibitors of ERK2 and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic inhibitors of ERK2 and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3896184